May 23rd 2023
Alik and colleagues noted "45% of IPV injuries involve the eyes. Many medical fields have increased IPV-related research; however, ophthalmology IPV research remains rare.”
February 10th 2023
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
Multidisciplinary Perspectives on Saving Sight – The Expanding Role of the Optometrist in Retinal Disease Care
05/31/2023
View More
Multidisciplinary Perspectives on Saving Sight – The Expanding Role of the Optometrist in Retinal Disease Care
05/31/2023
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
Late-breaking: Janssen announces data from 2 gene therapy programs
October 2nd 2022Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Faricimab eradicates center-involved DME faster than aflibercept
October 2nd 2022The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Continuous range-of-motion IOL scores high in patient satisfaction
September 30th 2022Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
Zika virus linked with fundus lesions in newborns in French territories
September 24th 2022This research team conducted a cross-sectional multicenter study to report the ocular fundus manifestations in infants with congenital ZIKV exposure in French Guiana, Martinique, and Guadeloupe, French West Indies.
Increased dosing for treatment of X-linked retinoschisis linked with inflammation in AAV-RS1 trials
September 20th 2022Investigators have reported good progress in determining how the disease works in the eye; however, a downside is the inflammation that seems to accompany treatment with increased dosing.
LUNA: First patient dosed with Ixo-vec in Phase 2 trial for treatment of wet AMD
September 17th 2022LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.
First patient enrolled in Phase 2 study of D-4517.2 for treatment of wet AMD, DME
September 8th 2022The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
First US patient with dry AMD dosed with autologous stem cell therapy
September 8th 2022According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.
OCS-01 improves macular thickness, visual acuity in patients with DME, according to Phase 2 data
September 7th 2022According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
LIGHT study: First analysis of gene therapy for RPE65 inherited retinal dystrophies
September 3rd 2022At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.